Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2002-05-20
2008-08-05
Foley, Shanon A. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S184100, C530S300000, C530S350000, C536S023200, C536S023700, C435S006120, C435S252100, C435S320100
Reexamination Certificate
active
07407664
ABSTRACT:
This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group AStreptococcus(GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies. In still further aspects, the invention also relates to methods for using the peptides, compositions, vaccines, or antibodies and methods for tailoring vaccines.
REFERENCES:
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 6063386 (2000-05-01), Dale et al.
patent: 6716433 (2004-04-01), Dale
patent: WO 94/06465 (1994-03-01), None
Beachey et al J Exp Med. Oct. 1, 1979;150(4):862-77.
Beachey et al J. Immunol. 136: 2287-2292, 1986b.
Beachey et al (J. Exp. Med. 163: 1451-1458, 1986 ).
Brandt et al. “Protective and Nonprotective Epitopes from Amino Termini of M Proteins from Australian Aboriginal Isolates and Reference Strains of Group A Streptococci.”Infection and Immunity68(12):6587-6594 (Dec. 2000).
Musser et al. “Genetic Diversity and Relationships amongStreptococcus pyogenesStrains Expressing Serotype M1 Protein: Recent Intercontinental Spread of a Subclone Causing Episodes of Invasive Disease.”Infection and Immunity63(3):994-1003 (Mar. 1995).
Beall et al., “Streptococcalemmtypes associated with T-agglutination types and the use of conservedemmrestriction fragment patterns for subtyping group A Streptococci.”J. Med. Micro.47:1-6 (1998).
Beall et al., “Survey ofemmGene Sequences and T-Antigen Types from SystemicStreptococcus pyogenesInfection Isolates Collected in San Francisco, California; Atlanta, Georgia; and Connecticut in 1994 and 1995.”J. Clin. Microbiol.35(5):1231-1235 (May 1997).
Brandt and Good, “Vaccine Strategies to Prevent Rheumatic Fever.”Immunol. Res.19(1):89-1031 (1999).
Dale et al., “Hyuaronated Capsule and Surface M Protein in Resistance to Opsonization of Group A Streptococci.”Infect. Immun.64(5):1495-1501 (May 1996).
Dale et al., “Passive Protection of Mice against Group A Streptococcal Pharyngeal Infection by Lipoteichoic Acid.”J. Infect. Dis.169:319-323 (Feb. 1994).
Davies et al., “Invasive group A streptococcal infections in Ontario, Canada. Ontario group A streptococcal study group.”N. Engl. J. Med.335(8):547-554 (Aug. 22, 1996).
Fischetti, “Streptococcal M Protein: Molecular Design and Biological Behavior.”Clin. Microbiol.2(3):285-314 (Jul. 1989).
Ji et al., “Intranasal Immunization with C5a peptidase Prevents Nasopharyngeal Colonization of Mice by Group A Streptococcus.”Infect. Immun.65(6):2080-2087 (Jun. 1997).
Kapur et al., “Vaccination with streptococcal extracellular cysteine protease (interleukin-1β convertase) protects mice against challenge with heterologous group A streptococci.”Microb. Pathogen.16:443-450 (Jun. 1994).
Lancefield, “Current knowledge of the type-specific M antigens of group A streptococci,”J. Immun.89:307-313 (1962).
Salvadori et al., “Group A Streptococcus-Liposome ELISA Antibody Titers to Group A Polysaccharide and Opsonophagocytic Capabilities of the Antibodies.”J. Infect. Dis.171:593-600 (Mar. 1995).
Veasey et al., “Resurgence of acute rheumatic fever in the intermountain region of the United States.”N. Engl. J. Med.316(8):42-47 (Feb. 19, 1987).
Ades Edwin W.
Beall Bernard W.
Carlone George M.
Sampson Jacquelyn S.
Baskar Padma v
Foley Shanon A.
Klarquist Sparkman LLP.
The United States of America as represented by the Secretary of
LandOfFree
Peptide vaccines against group A streptococci does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide vaccines against group A streptococci, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide vaccines against group A streptococci will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4019505